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2Abstract
Chromosomal rearrangements affecting the genes encoding complement factor H and the factor
H related proteins have been described in aHUS patients. To date such disorders have not been
described in other aHUS associated genes. We describe here a heterozygous 875,324bp
deletion encompassing the gene (CFI) encoding complement factor I and ten other genes. The
index case presented with aHUS and did not recover renal function. No abnormalities were
detected on Sanger sequencing of CFI but a low factor I level led to a multiplex ligation-
dependent probe amplification assay being undertaken. This showed a complete heterozygous
deletion of CFI. The extent of the deletion and the breakpoint were defined. In the Newcastle
aHUS cohort we have identified and report here 32 different CFI variants in 56 patients but to
date this is the only deletion that we have identified. This finding although rare does suggest
that screening for chromosomal rearrangements affecting CFI should be undertaken in all
aHUS patients particularly if the factor I level is unexplainably low.
Key Words: complement, factor I, atypical haemolytic uraemic syndrome, chromosomal
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3Introduction
Abnormalities affecting the serine protease complement factor I associated with atypical
haemolytic uremic syndrome (aHUS) include both mutations (Kavanagh, et al., 2005) and
autoantibodies (Kavanagh, et al., 2012). Mutations in CFI can lead to either impaired
secretion resulting in factor I deficiency or impaired function particularly of the serine protease
domain (Kavanagh, et al., 2013, Nilsson, et al., 2010). Mutations associated with factor I
deficiency include missense changes, nonsense changes and deletions of a single nucleotide
(Bienaime, et al., 2010). Larger deletions encompassing either the whole or part of CFI are
extremely rare. A homozygous deletion including exon 2 and part of intron 1 was found in a 6
year old boy who presented not with aHUS but with recurrent sepsis including an episode of
meningococcal disease (Alba-Dominguez, et al., 2012). We describe here a large heterozygous
deletion at 4q25, incorporating 11 genes including CFI, which leads to partial factor I
deficiency in association with aHUS.
Methods
The study was approved by Newcastle and North Tyneside 1 Research Ethics Committee, and
informed consent was obtained in accordance with the Declaration of Helsinki.
Case Report. A 36 year old male, presented with shortness of breath, vomiting and general
malaise. There was no history of diarrhoea. He took no regular medication and there was no
significant family history. Urinalysis showed +++ blood and ++ protein. Investigations
showed creatinine  1122 μmol/L, urea 39.4 mmol/L, haemoglobin 8.2 g/dL and platelets 83 x 
109/L. Blood film revealed occasional schistocytes. Prothrombin time, activated partial
thromboplastin time and fibrinogen were within normal limits. Routine autoantibody (ANCA,
anti-GBM) and virology (HBV, HCV, HIV) screening was negative. C4 was normal and C3
slightly decreased at 0.71 g/L (0.75-1-86). Subsequent C3 measurements ranged from 0.45 to
40.84 g/L. ADAMTS13 activity was normal. A renal ultrasound showed normal sized
hyperechoic kidneys without obstruction.
He commenced haemodialysis and subsequently a renal biopsy was performed which showed
a thrombotic microangiopathy with severe concentric fibro intimal expansion (Figure 1). He
did not recover renal function and is now undergoing peritoneal dialysis. Mutation screening
of CFH , CFI, CD46, C3, CFB and DGKE showed no abnormalities. Factor H autoantibodies
were negative and factor H concentration was normal at 0.69 g/l. Factor I concentration,
however, was low at 29 mg/l (normal range 38 -58). Multiplex ligation-dependent probe
amplification (MLPA) analysis revealed a heterozygous deletion encompassing all exons of
CFI (Figure 2). Screening of parental samples showed that he (II:1) had inherited this from his
father (I:1) who aged 63, is normotensive, has no abnormalities on urinalysis and has an eGFR
of 90 ml/min/1.73m2.
Measurement of complement components and screening for complement autoantibodies.
C3 and C4 levels were measured by rate nephelometry (Beckman Coulter Array 360). FH and
FI levels were measured by radial immunodiffusion (Binding Site). Screening for complement
autoantibodies were undertaken using ELISA as described previously(Kavanagh, et al., 2012,
Moore, et al., 2010)
Mutation screening of complement genes. Mutation screening of CFH (Richards, et al.,
2001), CFI (Kavanagh, et al., 2005), CFB (Kavanagh, et al., 2006), CD46 (Richards, et al.,
2003), C3 (Fremeaux-Bacchi, et al., 2008), and DGKE (Lemaire, et al., 2013) was undertaken
using Sanger sequencing as previously described. Screening for chromosomal rearrangements
affecting CFH, CFHR1, CFHR2, CFHR3, and CFHR5 was undertaken using multiplex
ligation-dependent probe amplification (MLPA) as previously described (Challis, et al., 2015).
5Genotyping. The CD46 SNPs -652A>G (rs2796267), -366A>G (rs2796268), IVS9 -78G>A
(rs1962149), IVS12 +638G>A (rs859705) and c.4070T>C (rs7144) which define the at-risk
CD46GGAAC haplotype and the CFH SNPs -331C>T (rs3753394), c.184G>A; p.Val62Ile
(rs800292), c.1204T>C p.Tyr402His (rs1061170), c.2016A>G; p.Gln672Gln (rs3753396),
IVS15 -543G>A intron 15 (rs1410996), c.2808G>T; p.Glu936Asp (rs1065489)) which define
the protective CFHCATAAG (known as CFH-H2) and at-risk CFHTGTGGT (known as CFH-H3)
haplotypes were genotyped using direct sequencing in both patient and parental samples as
described previously (Sansbury, et al., 2014).
Screening for chromosomal arrangements. Chromosomal rearrangements affecting CFI and
CD46 were screened for by MLPA using a proprietary kit from MRC Holland (SALSA MLPA
P296 aHUS, Netherlands). Probes in CFI are indicated (Figure 2A)
Defining the extent of the deletion and the breakpoint. To define the extent of the deletion
the CytoSure ISCA v2.0 (8x60k) array (Oxford Gene Technology) was used as per the
manufacturer’s protocol and arranged to human genome reference sequence (GRCh37) and
analysed using BlueFuse Multi software v3.3 (Illumina) (Supplementary Figure 1). To further
define the deletion microarray testing was performed using the Affymetrix CytoScan 750K
SNP array (Affymetrix, Santa Clara, CA). The data was analysed using the Chromosome
Analysis Suite v2.0 (Affymetrix) and the results were aligned to GRCh37 (Figures 3 and 4).
To fine map the deletion identified by the CytoScan 750K SNP array, custom single nucleotide
polymorphism (SNP) genotyping was undertaken. Common SNPs with an allele frequency of
~0.5 were identified (using UCSC genome browser (https://genome.ucsc.edu/index.html)
within the regions identified by the CytoScan 750K SNP array (proximal, Chr4:110,059,471-
110,070,698 and distal, Chr4:110,939,335-110,948,618). (Supplementary Tables 1 -3 and
Figures 4-5).
6A PCR product spanning the deletion was amplified using REDAccuTaq LA DNA Polymerase
(sigma, St Louis). The primers were forward 5’-ACAGTCAGCAGGGAAGAACG-3’ and
reverse 5’-AGTGCAAACCAGCCATCACT-3’. Products were resolved on a 0.6% agarose gel
(Figure 4B). Sanger sequencing of the PCR product was undertaken (Figure 6).
Results
The extent of the deletion. The CytoScan750K Array defined the extent of the deletion at
4q25. At the 5’ end of the deletion the last non deleted probe was at position Chr4:110,059,471
with the first deleted probe at position Chr4:110,070,698. At the 3’ end of the deletion the last
deleted probe was at position Chr4:110,939,335 with the next non deleted probe at position
Chr4:110,948,618. The maximum and minimum extent of the deletion as defined by the 750K
array are shown in Figure 4A.
The breakpoint. To further delineate the breakpoint, custom genotyping of common SNPs
was undertaken as shown on Figures 4A and 5. Informative SNPs (see Supplementary Tables
1-3) further narrowed the region of interest and allowed cross deletion long range PCR using
primers rs2704110 (f) and rs17041245 (r). An amplified product was found in the patient’s
father ( I:1) and the patient ( II:1) but not the mother (I:2.) (Figure 4B). Sanger sequencing
of this product showed the breakpoint to be between Chr4:110,069,101 and Chr4:110,944,425
resulting in a 875,324bp deletion (Figure 6A). This deletion spans 11 genes including factor I
(Figure 6B).
Genotyping. CFH and CD46 genotyping in patient and parental samples enabled us to infer
that the patient carries CFHCATAAG (protective H2 haplotype) on one allele and CFHTGTAGG
(H7 haplotype) on the other; and CD46GGAAC (at risk haplotype) on one allele and CD46AAGGT
on the other. His father (unaffected carrier of the CFI deletion) carries CFHCGCAGG (H1
7haplotype) on one allele and CFHTGTAGG (H7 haplotype) on the other; and CD46AAGGT on both
alleles.
CFI variants in the Newcastle aHUS cohort. In the Newcastle aHUS cohort we have
identified 32 different CFI variants in 56 patients that have either not been reported in control
populations or have an allele frequency equal to or less than 1% as derived from the data of the
Exome Aggregation Consortium (ExAC), Cambridge, MA (URL:
http://exac.broadinstitute.org) [accessed December 2015] (Table 1). The factor I
concentrations for the 26 variants where this is available are shown in Figure 7 along with
factor I concentrations for those aHUS patients in whom a variant in CFI has not been detected
by Sanger sequencing. Twenty-seven of the 32 different variants are non-synonymous and the
change in the amino acid is shown for 19 variants in a crystal structure of factor I in
Supplementary Figure 2. It was not possible to show the remaining 8 variants because the
surrounding structure is flexible in space and as such the coordinates could not be annotated.
Within the group of 56 patients who carry a CFI variant there are two (17 and 34) who carry
more than one rare CFI variant. Twenty two of the 56 patients also carry either a rare variant
in another complement gene and/or antibodies against factor H. There are three patients (7, 16
and 23) who carry a heterozygous CFI variant that leads to a frameshift and/or premature stop
codon. Factor I levels are available for two of them and both are low as expected.
Discussion
To our knowledge this is the first description in an aHUS patient of a large deletion that
encompasses CFI and thus results in factor I deficiency. The deletion includes exons 1-3 of
CO25A1 and 9 other entire genes. For three of these (CO25A1, LRIT3, EGF) a phenotype
has been described but only in homozygosity or compound heterozygosity (Table 2). No
phenotype has been described for the remaining six. That the father is asymptomatic despite
8being factor I deficient is in keeping with the reduced penetrance that is seen for aHUS
(Sansbury, et al., 2014). Genotyping of CFH and CD46 showed that he does not carry the at
risk CD46GGAAC haplotype whereas his affected son does.
In contrast we have identified 32 different CFI variants in 56 patients within the Newcastle
aHUS cohort. Three of these variants have previously been reported in aHUS patients in
association with low levels of factor I (Gly119Arg (Bienaime, et al., 2010, Maga, et al., 2010),
Val152Met (Westra, et al., 2010) and Gly287Arg (Maga, et al., 2010)). Gly119Arg has also
been associated with age-related macular degeneration again with low levels of factor
I(Kavanagh, et al., 2015). There are 4 patients in the Newcastle cohort who carry Gly119Arg,
factor I level is normal in two and low in two. Because factor I is an acute-phase protein the
use of absolute levels in individual patients is not sufficiently sensitive to exclude impaired
secretion secondary to a heterozygous genetic variant. In the patient that we describe here the
factor I level was low and Sanger sequencing of CFI did not show an abnormality to explain
this. If we had not undertaken MLPA then this individual would have fallen within the group
of aHUS patients said to have no identifiable mutation. Such patients are thought to have a
lower risk of recurrent disease post-transplant (Zuber, et al., 2011) and as such might not be
listed for transplantation with prophylactic eculizumab. Identification of the deletion led to
this patient being listed for a transplant with prophylactic eculizumab. In the Newcastle aHUS
cohort we have subsequently identified 6 other aHUS patients with a low factor I level who
had previously not been found to have any abnormality of CFI on Sanger sequencing. We
undertook MLPA in all of them and did not find any abnormalities. Thus, a deletion affecting
CFI appears to be a very rare finding in aHUS. This is in contrast to the genes encoding factor
H and the factor H related proteins where deletions secondary to both non-allelic homologous
recombination (NAHR) and microhomology-mediated end joining (MMEJ) can result in the
formation of aHUS-associated hybrid genes (Francis, et al., 2012, Venables, et al., 2006). The
9genomic structure of this region (1q32) is characterised by several large genomic duplications,
also known as low copy repeats (LCRs), resulting in a high degree of sequence identity
between CFH and the genes for the five factor H-related proteins. The resulting areas of macro-
and micro-homology predispose to NAHR and MMEJ. In contrast the genomic structure in
the vicinity of CFI at 4q25 shows little evidence of LCRs and one would, therefore, expect
chromosomal rearrangements in this region to be infrequent. However, because such a finding
has implications for the clinical management of a patient, particularly with regard to
transplantation, we are of the opinion that CFI MLPA should be undertaken in aHUS patients,
particularly in those with low factor I levels, as part of routine genetic screening.
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Legends to Figures
Figure 1. Photomicrographs of renal biopsy A) H&E stain (x40) shows vascular luminal
obliteration by sub-intimal expansion with fragmented red blood cells, and without fibrinoid
necrosis. B) The same vessel as in panel A stained with trichrome (x10) shows myxoid sub-
intimal expansion. C) Electron micrograph shows sub-endothelial electron lucent expansion
typical of acute thrombotic microangiopathy.
Figure 2. A) Representation of the CFI gene structure. The MLPA probes in CFI are denoted
by arrows and the distance between the probes shown. B) Multiplex ligation-dependent probe
amplification of CFI demonstrating the copy number ratio. The dosage quotient of ~0.5 for
I:1 (father) and II:1 (patient) is consistent with a deletion of one allele of CFI.
Figure 3. CytoScan 750K SNP array results. Microarray-based copy number analysis
performed using the CytoScan 750K SNP array and visualised using the Chromosome Analysis
Suite v2.0. A 8.69 Mb deletion was identified in II.1. The last non-deleted probes are located
at Chr4:110,059,471 and Chr4:110,948,617. The first deleted probes are located at
Chr4:110,070,698 and Chr4:110,939,335.
Figure 4. A) A CytoScan750K Array was performed to define the extent of the deletion in
chromosome 4. At the 5’ end of the deletion the last non deleted probe was at position
Chr4:110,059,471 with the first deleted probe at position Chr4:110,070,698. At the 3’ end of
the deletion the last deleted probe was at position Chr4:110,939,335 with the next non deleted
probe at position Chr4:110,948,618. The maximum and minimum extent of the deletion as
defined by the 750K array are highlighted in the diagram. To further delineate the breakpoint,
custom SNP genotyping of common SNPs was undertaken as highlighted. Informative SNPs
(see supplementary data) further narrowed the region of interest and allowed cross deletion
long range PCR using primers rs2704110 (f) and rs17041245 (r). B) The amplified product
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was run on a 0.6% agarose gel demonstrating amplified product in I:1 (father) and II:1 (patient)
but not I:2 (mother).
Figure 5. Extent of deletion as defined by custom SNP genotyping. Ampicon 8 (rs10021804)
covers a deleted region. Amplicons 3 (rs2704110) and 9 (rs17041245) cover non-deleted
regions. The maximum size of the deletion is 878740bp and the minimum size of the deletion
is 871899bp. The distance between amplicons 8 and 9 is 1931bp.
Figure 6. Sanger sequence trace of the breakpoint. A) This highlights a 875,324bp deletion
between Chr4:110,069,101 and 110,944,425. B) This deletion results in loss of exons 1-3 of
COL25A1, SEC24B-AS1, SEC24B ,CCDC109B, CASP6, PLA2G12A, CFI, GAR1, RRH, LRIT3
and EGF.
Figure 7. Serum FI levels by rare CFI variant in the Newcastle aHUS cohort. The lower limit
of normal (38 mg/l) is demonstrated by a dotted line. ^ represents a homozygous variant.
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Patient FI concentration
(mg/l)
Zygosity Nucleotide
change
Amino acid change ExAC allele
frequency
(%)
Additional variants/antibodies
1 35 Heterozygous Sporadic 148C>G Pro50Ala 0.011
2 40 Heterozygous Sporadic 355G>A Gly119Arg 0.053
3 63 Heterozygous Sporadic 355G>A Gly119Arg 0.053 CFH (c.2596+1G>C)
4 34 Heterozygous Sporadic 355G>A Gly119Arg 0.053
5 63 Heterozygous Sporadic 355G>A Gly119Arg 0.053 FH Ab
6 68 Heterozygous Sporadic 414G>T Met138Ile 0.0008
7 29 Heterozygous Sporadic 436G>A Trp145* 0
8 34 Heterozygous Sporadic 436A>C Ser146Arg 0.0016 CD46 Homozygous (c.469T>C; p.
Cys157Arg), FH Ab
9 36 Heterozygous Sporadic 454G>A Val152Met 0.003
10 79 Heterozygous Sporadic 482+6C>T 1.292
11 n/a Heterozygous Sporadic 482+6C>T 1.292 FH Ab
12 73 Heterozygous Sporadic 482+6C>T 1.292
13 n/a Heterozygous Sporadic 548A>G His183Arg 0.063
14 n/a Heterozygous Sporadic 560G>A Arg187Gln 0.012
15 94 Heterozygous Sporadic 612G>A Met204Ile 0
16 n/a Heterozygous Sporadic 651delG Ala219fs 0
17 54 Heterozygous Sporadic 667A>G Met223Val 0 FH Ab
17 54 Homozygous Sporadic 1315G>A Gly439Arg 0.027 FH Ab
18 n/a Heterozygous Sporadic 782G>A Gly261Asp 0.133 CFH ( c.2808G>T; p.Glu936Asp)
19 n/a Heterozygous Sporadic 782G>A Gly261Asp 0.133 CFH (c.3628C>T; p.Arg1210Cys)
20 37 Heterozygous Sporadic 859G>A Gly287Arg 0.003 FH Ab
21 55 Heterozygous Sporadic 859G>A Gly287Arg 0.003
22 54 Heterozygous Sporadic 859G>A Gly287Arg 0.003
23 29 Heterozygous Familial 893delC Ser298Leufs*10 0
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24 66 Heterozygous Sporadic 916A>G Ile306Val 0.048 CFB ( c.1598A>G; p.Lys533Arg )
25 82 Heterozygous Sporadic 1019T>C Ile340Thr 0.004
26 70 Heterozygous Sporadic 1166G>A Arg389His 0.002
27 41 Heterozygous Sporadic 1216C>T Arg406Cys 0.006 FH Ab
28 63 Heterozygous Sporadic 1217G>A Arg406His 0.006
29 51 Heterozygous Sporadic 1217G>A Arg406His 0.006
30 30 Heterozygous Sporadic 1246A>C Ile416Leu 0.111
31 n/a Heterozygous Sporadic 1246A>C Ile416Leu 0.111
32 n/a Heterozygous Sporadic 1253A>T His418Leu 0.001 CD46 (c.390-2A>G)
33 48 Heterozygous Sporadic 1268C>A Ala423Glu 0.002 CFB (c.1598A>G; p.Lys533Arg)
34 33 Heterozygous Sporadic 1402A>G Ile468Val 0 CD46 homozygous (c.100G>A;
p.Ala34Thr)
34 33 Heterozygous Sporadic 1642G>C Glu548Gln 0.072 CD46 homozygous (c.100G>A;
p.Ala34Thr)
35 41 Homozygous Sporadic 1456T>C Trp486Arg 0 FH Ab
36 56 Heterozygous Sporadic 1534+5G>T 0.893
37 90 Heterozygous Sporadic 1534+5G>T 0.893 C3 (c.485C>G; p.Thr162Arg,
c.2203C>T; p.Arg753Trp)
38 68 Heterozygous Sporadic 1534+5G>T 0.893 FH Ab
39 67 Heterozygous Sporadic 1534+5G>T 0.893 CFH (c.3616C>T; p.Arg1206Cys),
CFB (c.724A>C; p. Ile242Leu)
40 53 Heterozygous Sporadic 1534+5G>T 0.893 CFH (c.351-4dup)
41 90 Heterozygous Sporadic 1534+5G>T 0.893
42 n/a Heterozygous Sporadic 1534+5G>T 0.893
43 69 Heterozygous Sporadic 1534+5G>T 0.893
44 68 Heterozygous Sporadic 1534+5G>T 0.893
45 56 Heterozygous Sporadic 1534+5G>T 0.893 C3 (c.485C>G; p.Thr162Arg,
c.2203C>T; p.Arg753Trp)
46 30 Heterozygous Sporadic 1534+5G>T 0.893
47 48 Heterozygous Sporadic 1534+5G>T 0.893
48 52 Heterozygous Sporadic 1534+5G>T 0.893
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Table 1 CFI variants in the Newcastle aHUS cohort. The ExAC allele frequency is taken from http://exac.broadinstitute.org/.Normal
range for FI concentration is (38-58 mg/l). n/a not available.
49 70 Heterozygous Sporadic 1534+5G>T 0.893 CFH (c.3398C>G; p.Ser1133*)
50 85 Heterozygous Sporadic 1555G>A Asp519Asn 0.002
51 26 Heterozygous Sporadic 1635T>A Ser545Arg 0 CFHR1/CFH hybrid
52 60 Heterozygous Sporadic 1657C>T Pro553Ser 0.127
53 63 Heterozygous Sporadic 1657C>T Pro553Ser 0.127
54 86 Heterozygous Sporadic 1657C>T Pro553Ser 0.127
55 89 Heterozygous Familial 1657C>T Pro553Ser 0.127 CFH (c.3648dupA;Trp1157fs)
56 41 Heterozygous Sporadic 1733T>C Ile578Thr 0.003
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Gene Gene MIM Phenotype Phenotype MIM Inheritance
COL25A1 61004 FIBROSIS OF EXTRAOCULAR MUSCLES,
CONGENITAL, 5; CFEOM5
616219 Recessive
SEC24B-AS1 and SEC24B 607184 None described.
CCDC109B n/a None described
CASP6 601532 None described
PLA2G12A 611652 None described
GAR1 606468 None described
RRH 605224 None described
LRIT3 615004 NIGHT BLINDNESS, CONGENITAL
STATIONARY, TYPE 1F; CSNB1F
615058 Recessive
EGF 131530 HYPOMAGNESEMIA 4, RENAL; HOMG4 611718 Recessive
Table 2. Genes within the deletion and associated phenotype.
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